The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections
Abstract
Airway mucus dysfunction and impaired immunological defenses are hallmarks of several lung diseases, including asthma, cystic fibrosis, and chronic obstructive pulmonary diseases, and are mostly causative factors in bacterial-biofilm-associated respiratory tract infections. Bacteria residing within the biofilm architecture pose a complex challenge in clinical settings due to their increased tolerance to currently available antibiotics and host immune responses, resulting in chronic infections with high recalcitrance and high rates of morbidity and mortality. To address these unmet clinical needs, potential anti-biofilm therapeutic strategies are being developed to effectively control bacterial biofilm. This review focuses on recent advances in the development and application of nanoparticulate drug delivery systems for the treatment of biofilm-associated respiratory tract infections, especially addressing the respiratory barriers of concern for biofilm accessibility and the various types of nanoparticles used to combat biofilms. Understanding the obstacles facing pulmonary drug delivery to bacterial biofilms and nanoparticle-based approaches to combatting biofilm may encourage researchers to explore promising treatment modalities for bacterial-biofilm-associated chronic lung infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Surveys catalog metal and metal-oxide particles that include silver (Ag), zinc oxide (ZnO), and titanium dioxide (TiO2), as well as mesoporous silica frameworks, polymer and lipid carriers, and hybrid systems that restore antibiotic activity at lower doses [193,194].”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [194]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
Microfabrication of human organs-on-chips
Huh, D., Kim, H. J., Fraser, J. P., Shea, D. E., Khan, M., Bahinski, A., Hamilton, G. A., & Ingber, D. E. (2013) · Nature Protocols · doi:10.1038/nprot.2013.137 · Cited by 712
Deppisch, C., Herrmann, G., Graepler-Mainka, U., Wirtz, H., Heyder, S., Engel, C., Marschal, M., Miller, C. C., & Riethmüller, J. (2016) · Infection · doi:10.1007/s15010-016-0879-x · Cited by 115
Suk, J. S., Boylan, N. J., Trehan, K., Tang, B. C., Schneider, C. S., Lin, J.-M. G., Boyle, M. P., Zeitlin, P. L., Lai, S. K., Cooper, M. J., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.160 · Cited by 94
Research works printed but not linked: 252
- Azoulay, 2020, Diagnosis of severe respiratory infections in immunocompromised patients, Intensive Care Med., 46, 298, 10.1007/s00134-019-05906-5 · DOI · Paper page
- Hutchinson, 2018, Influenza Virus, Trends Microbiol., 26, 809, 10.1016/j.tim.2018.05.013 · DOI
- Langedijk, 2023, Respiratory syncytial virus infection and novel interventions, Nat. Rev. Microbiol., 21, 734, 10.1038/s41579-023-00919-w · DOI · Paper page
- Borczuk, A.C., and Yantiss, R.K. (2022). The pathogenesis of coronavirus-19 disease. J. Biomed. Sci., 29. · DOI
- Rostami, A., Liu, M.-C., Xu, Q., Li, T.-T., Wang, T., Jiang, B.-G., Lv, C.-L., Zhang, X.-A., Liu, W., and Fang, L.-Q. (2023). Prevalence of human infection with respiratory adenovirus in China: A systematic review and meta-analysis. PLoS Neglected Trop. Dis., 17. · DOI
- Shang, 2020, Viral pneumonia in China: From surveillance to response, Lancet Public. Health, 5, e633, 10.1016/S2468-2667(20)30264-4 · doi:10.1016/s2468-2667(20)30264-4
- Cone, 2009, Barrier properties of mucus, Adv. Drug Deliv. Rev., 61, 75, 10.1016/j.addr.2008.09.008 · DOI · Paper page
- Vanaki, S.M., Holmes, D., Saha, S.C., Chen, J., Brown, R.J., and Jayathilake, P.G. (2020). Muco-ciliary clearance: A review of modelling techniques. J. Biomech., 99. · DOI
- Fahy, 2010, Airway mucus function and dysfunction, N. Engl. J. Med., 363, 2233, 10.1056/NEJMra0910061 · DOI · Paper page
- Ding, 2021, Pulmonary biofilm-based chronic infections and inhaled treatment strategies, Int. J. Pharm., 604, 120768, 10.1016/j.ijpharm.2021.120768 · DOI
- Ciofu, 2015, Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients, Adv. Drug Deliv. Rev., 85, 7, 10.1016/j.addr.2014.11.017 · DOI · Paper page
- Potera, 1999, Microbiology—Forging a link between biofilms and disease, Science, 283, 1837, 10.1126/science.283.5409.1837 · DOI · Paper page
- Costerton, 1999, Bacterial biofilms: A common cause of persistent infections, Science, 284, 1318, 10.1126/science.284.5418.1318 · DOI · Paper page
- Ciofu, 2022, Tolerance and resistance of microbial biofilms, Nat. Rev. Microbiol., 20, 621, 10.1038/s41579-022-00682-4 · DOI · Paper page
- Sharma, 2021, Advances in pulmonary drug delivery targeting microbial biofilms in respiratory diseases, Nanomedicine, 16, 1905, 10.2217/nnm-2021-0057 · DOI
- Zhang, 2022, Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections, Int. J. Pharm., 616, 121507, 10.1016/j.ijpharm.2022.121507 · DOI
- Selmani, 2022, Nanoparticles: From synthesis to applications and beyond, Adv. Colloid. Interface Sci., 303, 102640, 10.1016/j.cis.2022.102640 · DOI · Paper page
- Wu, 2018, Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties, Adv. Drug Deliv. Rev., 124, 150, 10.1016/j.addr.2017.10.001 · DOI · Paper page
- Murgia, 2018, The role of mucus on drug transport and its potential to affect therapeutic outcomes, Adv. Drug Deliv. Rev., 124, 82, 10.1016/j.addr.2017.10.009 · DOI · Paper page
- Leal, 2017, Physicochemical properties of mucus and their impact on transmucosal drug delivery, Int. J. Pharm., 532, 555, 10.1016/j.ijpharm.2017.09.018 · DOI · Paper page
- Button, 2012, A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia, Science, 337, 937, 10.1126/science.1223012 · DOI · Paper page
- Sears, 2011, Mucociliary interactions and mucus dynamics in ciliated human bronchial epithelial cell cultures, Am. J. Physiol. Lung Cell Mol. Physiol., 301, L181, 10.1152/ajplung.00321.2010 · DOI
- Liu, 2015, Developments of mucus penetrating nanoparticles, Asian J. Pharm. Sci., 10, 275, 10.1016/j.ajps.2014.12.007 · DOI · Paper page
- Song, 2021, Modeling Airway Dysfunction in Asthma Using Synthetic Mucus Biomaterials, ACS Biomater. Sci. Eng., 7, 2723, 10.1021/acsbiomaterials.0c01728 · DOI
- Patarin, 2020, Rheological analysis of sputum from patients with chronic bronchial diseases, Sci. Rep., 10, 15685, 10.1038/s41598-020-72672-6 · doi:10.1038/s41598-020-72672-6
- Duncan, 2016, Microstructural alterations of sputum in cystic fibrosis lung disease, JCI Insight, 1, e88198, 10.1172/jci.insight.88198 · DOI
- Linssen, 2021, Neutrophil Extracellular Traps Increase Airway Mucus Viscoelasticity and Slow Mucus Particle Transit, Am. J. Respir. Cell Mol. Biol., 64, 69, 10.1165/rcmb.2020-0168OC · DOI
- Lai, 2009, Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv. Drug Deliv. Rev., 61, 158, 10.1016/j.addr.2008.11.002 · DOI · Paper page
- Schneider, 2017, Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation, Sci. Adv., 3, e1601556, 10.1126/sciadv.1601556 · DOI · Paper page
- Xu, 2015, Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo, ACS Nano, 9, 9217, 10.1021/acsnano.5b03876 · DOI · Paper page
- Seiler, 2014, Regulation and function of antimicrobial peptides in immunity and diseases of the lung, Protein Pept. Lett., 21, 341, 10.2174/09298665113206660100 · doi:10.2174/09298665113206660100
- Lecaille, 2016, Antimicrobial proteins and peptides in human lung diseases: A friend and foe partnership with host proteases, Biochimie, 122, 151, 10.1016/j.biochi.2015.08.014 · DOI
- James, 2008, Biofilms in chronic wounds, Wound Repair. Regen., 16, 37, 10.1111/j.1524-475X.2007.00321.x · DOI · Paper page
- Haesler, 2019, Clinical indicators of wound infection and biofilm: Reaching international consensus, J. Wound Care, 28, s4, 10.12968/jowc.2019.28.Sup3b.S4 · DOI
- Xie, 2022, Cholesterol Microdomain Enhances the Biofilm Eradication of Antibiotic Liposomes, Adv. Healthc. Mater., 11, 2101745, 10.1002/adhm.202101745 · DOI
- Jean-Pierre, V., Boudet, A., Sorlin, P., Menetrey, Q., Chiron, R., Lavigne, J.-P., and Marchandin, H. (2022). Biofilm Formation by Staphylococcus aureus in the Specific Context of Cystic Fibrosis. Int. J. Mol. Sci., 24. · DOI
- Weiser, 2018, Streptococcus pneumoniae: Transmission, colonization and invasion, Nat. Rev. Microbiol., 16, 355, 10.1038/s41579-018-0001-8 · DOI · Paper page
- Margalit, 2020, Clinical correlates of nocardiosis, Sci. Rep., 10, 14272, 10.1038/s41598-020-71214-4 · DOI
- Xiu, 2023, Ultrasound-responsive catalytic microbubbles enhance biofilm elimination and immune activation to treat chronic lung infections, Sci. Adv., 9, eade5446, 10.1126/sciadv.ade5446 · DOI
- Bajire, S.K., Prabhu, A., Bhandary, Y.P., Irfan, K.M., and Shastry, R.P. (2023). 7-Ethoxycoumarin rescued Caenorhabditis elegans from infection of COPD derived clinical isolate Pseudomonas aeruginosa through virulence and biofilm inhibition via targeting Rhl and Pqs quorum sensing systems. World J. Microbiol. Biotechnol., 39. · DOI
- Ricard, 2018, Pathophysiology of Escherichia coli pneumonia: Respective contribution of pathogenicity islands to virulence, Int. J. Med. Microbiol., 308, 290, 10.1016/j.ijmm.2018.01.003 · DOI
- Kharga, K., Dhar, I., Kashyap, S., Sengupta, S., Kumar, D., and Kumar, L. (2023). Zingerone inhibits biofilm formation and enhances antibiotic efficacy against Salmonella biofilm. World J. Microbiol. Biotechnol., 39. · DOI
- Li, Y., and Ni, M. (2023). Regulation of biofilm formation in Klebsiella pneumoniae. Front. Microbiol., 14. · DOI
- Marienborg, 2023, The alginate polymer OligoG alters susceptibility of biofilm-embedded non-typeable Haemophilus influenzae to ampicillin and ciprofloxacin, JAC-Antimicrob. Resist., 5, dlad046, 10.1093/jacamr/dlad046 · doi:10.1093/jacamr/dlad046
- Earle, 2023, Pathogenicity and virulence of Aspergillus fumigatus, Virulence, 14, 2172264, 10.1080/21505594.2023.2172264 · DOI
- Bouyssi, A., Déméautis, T., Trecourt, A., Delles, M., Agostini, F., Monneret, G., Glehen, O., Wallon, M., Persat, F., and Devouassoux, G. (2023). Characterization of Lung Inflammatory Response to Aspergillus fumigatus Spores. J. Fungi, 9. · DOI
- Linder, K.A., Kauffman, C.A., and Miceli, M.H. (2023). Blastomycosis: A Review of Mycological and Clinical Aspects. J. Fungi, 9. · DOI
- Rather, M.A., Saha, D., Bhuyan, S., Jha, A.N., and Mandal, M. (2022). Quorum Quenching: A Drug Discovery Approach Against Pseudomonas aeruginosa. Microbiol. Res., 264. · doi:10.1016/j.micres.2022.127173
- Hansen, 2008, Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience, J. Cyst. Fibros., 7, 523, 10.1016/j.jcf.2008.06.009 · DOI
- Rumbaugh, 2020, Biofilm dispersion, Nat. Rev. Microbiol., 18, 571, 10.1038/s41579-020-0385-0 · DOI · Paper page
- Arora, 2015, Nitric Oxide Regulation of Bacterial Biofilms, Biochemistry, 54, 3717, 10.1021/bi501476n · DOI · Paper page
- Bansil, 2018, The biology of mucus: Composition, synthesis and organization, Adv. Drug Deliv. Rev., 124, 3, 10.1016/j.addr.2017.09.023 · DOI · Paper page
- Curran, 2018, Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection, Am. J. Respir. Crit. Care Med., 197, 708, 10.1164/rccm.201705-1043SO · DOI · Paper page
- Proft, 2009, Pili in Gram-negative and Gram-positive bacteria—Structure, assembly and their role in disease, Cell Mol. Life Sci., 66, 613, 10.1007/s00018-008-8477-4 · DOI · Paper page
- Whiteley, 2017, Progress in and promise of bacterial quorum sensing research, Nature, 551, 313, 10.1038/nature24624 · DOI · Paper page
- Koo, 2017, Targeting microbial biofilms: Current and prospective therapeutic strategies, Nat. Rev. Microbiol., 15, 740, 10.1038/nrmicro.2017.99 · DOI · Paper page
- Yang, 2011, Distinct roles of extracellular polymeric substances in Pseudomonas aeruginosa biofilm development, Environ. Microbiol., 13, 1705, 10.1111/j.1462-2920.2011.02503.x · DOI · Paper page
- Giltner, 2005, DNA binding: A novel function of Pseudomonas aeruginosa type IV pili, J. Bacteriol., 187, 1455, 10.1128/JB.187.4.1455-1464.2005 · DOI · Paper page
- Yang, 2009, Pyoverdine and PQS mediated subpopulation interactions involved in Pseudomonas aeruginosa biofilm formation, Mol. Microbiol., 74, 1380, 10.1111/j.1365-2958.2009.06934.x · DOI · Paper page
- Bjarnsholt, 2013, Applying insights from biofilm biology to drug development—Can a new approach be developed?, Nat. Rev. Drug Discov., 12, 791, 10.1038/nrd4000 · DOI · Paper page
- Klausen, 2003, Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants, Mol. Microbiol., 48, 1511, 10.1046/j.1365-2958.2003.03525.x · DOI · Paper page
- Costerton, 2005, Phenotypic differentiation and seeding dispersal in non-mucoid and mucoid Pseudomonas aeruginosa biofilms, Microbiology, 151, 1569, 10.1099/mic.0.27536-0 · DOI · Paper page
- Flemming, 2010, The biofilm matrix, Nat. Rev. Microbiol., 8, 623, 10.1038/nrmicro2415 · DOI · Paper page
- Byrd, 2009, Genetic and biochemical analyses of the Pseudomonas aeruginosa Psl exopolysaccharide reveal overlapping roles for polysaccharide synthesis enzymes in Psl and LPS production, Mol. Microbiol., 73, 622, 10.1111/j.1365-2958.2009.06795.x · DOI · Paper page
- Mann, 2012, Pseudomonas biofilm matrix composition and niche biology, FEMS Microbiol. Rev., 36, 893, 10.1111/j.1574-6976.2011.00322.x · DOI · Paper page
- Ma, 2012, The roles of biofilm matrix polysaccharide Psl in mucoid Pseudomonas aeruginosa biofilms, FEMS Immunol. Med. Microbiol., 65, 377, 10.1111/j.1574-695X.2012.00934.x · DOI
- Ma, L., Conover, M., Lu, H., Parsek, M.R., Bayles, K., and Wozniak, D.J. (2009). Assembly and development of the Pseudomonas aeruginosa biofilm matrix. PLoS Pathog., 5. · DOI · Paper page
- Colvin, K.M., Gordon, V.D., Murakami, K., Borlee, B.R., Wozniak, D.J., Wong, G.C.L., and Parsek, M.R. (2011). The Pel Polysaccharide Can Serve a Structural and Protective Role in the Biofilm Matrix of Pseudomonas aeruginosa. PLoS Pathog., 7. · DOI · Paper page
- Jennings, 2015, Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the Pseudomonas aeruginosa biofilm matrix, Proc. Natl. Acad. Sci. USA, 112, 11353, 10.1073/pnas.1503058112 · DOI · Paper page
- Rossi, 2021, Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis, Nat. Rev. Microbiol., 19, 331, 10.1038/s41579-020-00477-5 · DOI · Paper page
- Maurice, 2018, Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections, Am. J. Respir. Cell Mol. Biol., 58, 428, 10.1165/rcmb.2017-0321TR · DOI · Paper page
- Hoiby, 2017, Diagnosis of biofilm infections in cystic fibrosis patients, APMIS, 125, 339, 10.1111/apm.12689 · DOI
- Paetzold, 2020, Characterization of different alginate lyases for dissolving Pseudomonas aeruginosa biofilms, Sci. Rep., 10, 9390, 10.1038/s41598-020-66293-2 · DOI
- Wan, 2020, Alginate Lyase Guided Silver Nanocomposites for Eradicating Pseudomonas aeruginosa from Lungs, ACS Appl. Mater. Interfaces, 12, 9050, 10.1021/acsami.9b21815 · DOI
- Powell, L.C., Pritchard, M.F., Ferguson, E.L., Powell, K.A., Patel, S.U., Rye, P.D., Sakellakou, S.M., Buurma, N.J., Brilliant, C.D., and Copping, J.M. (2018). Targeted disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate oligosaccharides. NPJ Biofilms Microbiomes, 4. · DOI · Paper page
- Cendra, M.D., and Torrents, E. (2021). Pseudomonas aeruginosa biofilms and their partners in crime. Biotechnol. Adv., 49. · DOI · Paper page
- Sarkar, 2020, Release mechanisms and molecular interactions of Pseudomonas aeruginosa extracellular DNA, Appl. Microbiol. Biotechnol., 104, 6549, 10.1007/s00253-020-10687-9 · DOI
- Das, T., and Manefield, M. (2012). Pyocyanin promotes extracellular DNA release in Pseudomonas aeruginosa. PLoS ONE, 7. · DOI · Paper page
- Mulcahy, H., Charron-Mazenod, L., and Lewenza, S. (2008). Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms. PLoS Pathog., 4. · DOI · Paper page
- Wang, 2015, The exopolysaccharide Psl-eDNA interaction enables the formation of a biofilm skeleton in Pseudomonas aeruginosa, Environ. Microbiol. Rep., 7, 330, 10.1111/1758-2229.12252 · DOI · Paper page
- Saunders, 2020, Extracellular DNA Promotes Efficient Extracellular Electron Transfer by Pyocyanin in Pseudomonas aeruginosa Biofilms, Cell, 182, 919, 10.1016/j.cell.2020.07.006 · DOI · Paper page
- Chiang, 2013, Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms, Antimicrob. Agents Chemother., 57, 2352, 10.1128/AAC.00001-13 · DOI · Paper page
- Russo, 2010, Extracellular DNA: A major proinflammatory component of Pseudomonas aeruginosa biofilms, J. Immunol., 184, 6386, 10.4049/jimmunol.0901640 · DOI
- Caiazza, 2005, Rhamnolipids modulate swarming motility patterns of Pseudomonas aeruginosa, J. Bacteriol., 187, 7351, 10.1128/JB.187.21.7351-7361.2005 · DOI · Paper page
- Zheng, 2017, Synthetic analogs of rhamnolipids modulate structured biofilms formed by rhamnolipid-nonproducing mutant of Pseudomonas aeruginosa, Bioorg. Med. Chem., 25, 1830, 10.1016/j.bmc.2017.01.042 · doi:10.1016/j.bmc.2017.01.042
- Wang, 2013, Rhamnolipid but not motility is associated with the initiation of biofilm seeding dispersal of Pseudomonas aeruginosa strain PA17, J. Biosci., 38, 149, 10.1007/s12038-012-9297-0 · DOI
- Domingue, 2020, Host responses to mucosal biofilms in the lung and gut, Mucosal Immunol., 13, 413, 10.1038/s41385-020-0270-1 · DOI
- Hoiby, 2010, Pseudomonas aeruginosa biofilms in cystic fibrosis, Future Microbiol., 5, 1663, 10.2217/fmb.10.125 · DOI · Paper page
- Parks, 2009, Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: Human F-actin and DNA as targets for therapy, J. Med. Microbiol., 58, 492, 10.1099/jmm.0.005728-0 · DOI
- Pedraz, 2020, Gradual adaptation of facultative anaerobic pathogens to microaerobic and anaerobic conditions, FASEB J., 34, 2912, 10.1096/fj.201902861R · DOI
- Kamath, 2017, Pseudomonas aeruginosa Proteome under Hypoxic Stress Conditions Mimicking the Cystic Fibrosis Lung, J. Proteome Res., 16, 3917, 10.1021/acs.jproteome.7b00561 · DOI
- Zhao, 2018, Oxygen effects on rhamnolipids production by Pseudomonas aeruginosa, Microb. Cell Fact., 17, 39, 10.1186/s12934-018-0888-9 · DOI
- Zhang, 2019, Pseudomonas aeruginosa Regulatory Protein AnvM Controls Pathogenicity in Anaerobic Environments and Impacts Host Defense, mBio, 10, 10, 10.1128/mBio.01362-19 · DOI
- Baral, 2020, Strategic Moves of “Superbugs” Against Available Chemical Scaffolds: Signaling, Regulation, and Challenges, ACS Pharmacol. Transl., 3, 373, 10.1021/acsptsci.0c00005 · DOI
- Olivares, E., Badel-Berchoux, S., Provot, C., Prevost, G., Bernardi, T., and Jehl, F. (2019). Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections. Front. Microbiol., 10. · DOI · Paper page
- Uruen, C., Chopo-Escuin, G., Tommassen, J., Mainar-Jaime, R.C., and Arenas, J. (2021). Biofilms as Promoters of Bacterial Antibiotic Resistance and Tolerance. Antibiotics, 10. · DOI · Paper page
- Paranjape, 2019, Comparison of Starvation-Induced Persister Cells with Antibiotic-Induced Persister Cells, Curr. Microbiol., 76, 1495, 10.1007/s00284-019-01777-7 · DOI
- Moldoveanu, 2021, Impact of bacterial persisters on their host, Curr. Opin. Microbiol., 59, 65, 10.1016/j.mib.2020.07.006 · DOI · Paper page
- Chattagul, 2021, Transcriptomics Analysis Uncovers Transient Ceftazidime Tolerance in Burkholderia Biofilms, ACS Infect. Dis., 7, 2324, 10.1021/acsinfecdis.1c00003 · DOI
- Poudyal, 2018, The PA3177 Gene Encodes an Active Diguanylate Cyclase That Contributes to Biofilm Antimicrobial Tolerance but Not Biofilm Formation by Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 62, 10, 10.1128/AAC.01049-18 · DOI
- Poudyal, 2018, The ABC of Biofilm Drug Tolerance: The MerR-Like Regulator BrlR Is an Activator of ABC Transport Systems, with PA1874-77 Contributing to the Tolerance of Pseudomonas aeruginosa Biofilms to Tobramycin, Antimicrob. Agents Chemother., 62, 10, 10.1128/AAC.01981-17 · DOI
- Gao, 2020, Size and Charge Adaptive Clustered Nanoparticles Targeting the Biofilm Microenvironment for Chronic Lung Infection Management, ACS Nano, 14, 5686, 10.1021/acsnano.0c00269 · DOI · Paper page
- Yang, 2023, Self-Adaptive Antibiofilm Effect and Immune Regulation by Hollow Cu2MoS4 Nanospheres for Treatment of Implant Infections, ACS Appl. Mater. Interfaces, 15, 18720, 10.1021/acsami.3c01928 · DOI
- Hu, 2023, Hybrid Biomimetic Membrane Coated Particles-Mediated Bacterial Ferroptosis for Acute MRSA Pneumonia, ACS Nano, 17, 11692, 10.1021/acsnano.3c02365 · DOI
- Zhao, 2019, Bioinspired Heteromultivalent Ligand-Decorated Nanotherapeutic for Enhanced Photothermal and Photodynamic Therapy of Antibiotic-Resistant Bacterial Pneumonia, ACS Appl. Mater. Interfaces, 11, 39648, 10.1021/acsami.9b15118 · DOI
- Liu, 2020, Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery, Drug Discov. Today, 25, 150, 10.1016/j.drudis.2019.09.023 · DOI · Paper page
- Yue, 2023, Inhaled drug delivery: Past, present, and future, Nano Today, 52, 101942, 10.1016/j.nantod.2023.101942 · DOI
- Chen, 2021, Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung, Expert. Opin. Drug Deliv., 18, 595, 10.1080/17425247.2021.1854222 · DOI
- Pangeni, 2023, Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers, Int. J. Pharm., 634, 122661, 10.1016/j.ijpharm.2023.122661 · DOI
- Zhao, 2022, Elucidating inhaled liposome surface charge on its interaction with biological barriers in the lung, Eur. J. Pharm. Biopharm., 172, 101, 10.1016/j.ejpb.2022.01.009 · DOI
- Ma, 2023, pH-Mediated Mucus Penetration of Zwitterionic Polydopamine-Modified Silica Nanoparticles, Nano Lett., 23, 7552, 10.1021/acs.nanolett.3c02128 · DOI
- Martins, 2018, Chemical modification of drug molecules as strategy to reduce interactions with mucus, Adv. Drug Deliv. Rev., 124, 98, 10.1016/j.addr.2017.09.020 · DOI
- Chono, 2008, Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes, J. Drug Target., 14, 557, 10.1080/10611860600834375 · DOI
- Seydoux, 2016, Pulmonary delivery of cationic gold nanoparticles boost antigen-specific CD4(+) T Cell Proliferation, Nanomed-Nanotechnol., 12, 1815, 10.1016/j.nano.2016.02.020 · DOI
- Falahati, 2023, Engineering of pulmonary surfactant corona on inhaled nanoparticles to operate in the lung system, Nano Today, 52, 101998, 10.1016/j.nantod.2023.101998 · DOI
- Hidalgo, 2019, The Lord of the Lungs: The essential role of pulmonary surfactant upon inhalation of nanoparticles, Eur. J. Pharm. Biopharm., 144, 230, 10.1016/j.ejpb.2019.09.020 · DOI
- Liu, 2019, Nanotechnology-based antimicrobials and delivery systems for biofilm-infection control, Chem. Soc. Rev., 48, 428, 10.1039/C7CS00807D · DOI · Paper page
- Peulen, 2011, Diffusion of Nanoparticles in a Biofilm, Environ. Sci. Technol., 45, 3367, 10.1021/es103450g · DOI · Paper page
- Blanco, 2015, Principles of nanoparticle design for overcoming biological barriers to drug delivery, Nat. Biotechnol., 33, 941, 10.1038/nbt.3330 · DOI · Paper page
- Zou, 2016, Mechanisms of the Antimicrobial Activities of Graphene Materials, J. Am. Chem. Soc., 138, 2064, 10.1021/jacs.5b11411 · DOI · Paper page
- Elbourne, 2019, Multi-directional electrodeposited gold nanospikes for antibacterial surface applications, Nanoscale Adv., 1, 203, 10.1039/C8NA00124C · DOI
- Elahi, 2018, Recent biomedical applications of gold nanoparticles: A review, Talanta, 184, 537, 10.1016/j.talanta.2018.02.088 · DOI · Paper page
- Nicolae-Maranciuc, A., Chicea, D., and Chicea, L.M. (2022). Ag Nanoparticles for Biomedical Applications—Synthesis and Characterization—A Review. Int. J. Mol. Sci., 23. · DOI
- Jamkhande, 2019, Metal nanoparticles synthesis: An overview on methods of preparation, advantages and disadvantages, and applications, J. Drug Deliv. Sci. Technol., 53, 101174, 10.1016/j.jddst.2019.101174 · DOI · Paper page
- Rani, 2023, Plant-mediated synthesis of nanoparticles and their applications: A review, Mater. Res. Bull., 163, 112233, 10.1016/j.materresbull.2023.112233 · DOI · Paper page
- Jadoun, 2022, Synthesis of nanoparticles using microorganisms and their applications: A review, Environ. Chem. Lett., 20, 3153, 10.1007/s10311-022-01444-7 · doi:10.1007/s10311-022-01444-7
- Khan, 2022, Prospects of algae-based green synthesis of nanoparticles for environmental applications, Chemosphere, 293, 133571, 10.1016/j.chemosphere.2022.133571 · DOI · Paper page
- Kashyap, 2021, Synthesis, characterization and application of intracellular Ag/AgCl nanohybrids biosynthesized in Scenedesmus sp. as neutral lipid inducer and antibacterial agent, Environ. Res., 201, 111499, 10.1016/j.envres.2021.111499 · DOI
- Zheng, 2018, Antimicrobial silver nanomaterials, Coord. Chem. Rev., 357, 1, 10.1016/j.ccr.2017.11.019 · DOI · Paper page
- Mozafari, 2021, Antimicrobial Applications of Nanoliposome Encapsulated Silver Nanoparticles: A Potential Strategy to Overcome Bacterial Resistance, Curr. Nanosci., 17, 26, 10.2174/18756786MTA4iMTAi3 · doi:10.2174/18756786mta4imtai3
- Mirzajani, 2011, Antibacterial effect of silver nanoparticles on Staphylococcus aureus, Res. Microbiol., 162, 542, 10.1016/j.resmic.2011.04.009 · DOI · Paper page
- Ansari, 2014, Interaction of silver nanoparticles with Escherichia coli and their cell envelope biomolecules, J. Basic. Microbiol., 54, 905, 10.1002/jobm.201300457 · doi:10.1002/jobm.201300457
- Garavand, 2021, Incorporation of silver nanoparticles into active antimicrobial nanocomposites: Release behavior, analyzing techniques, applications and safety issues, Adv. Colloid. Interfac., 293, 102440, 10.1016/j.cis.2021.102440 · DOI
- Haidari, 2022, Polycationic Silver Nanoclusters Comprising Nanoreservoirs of Ag(+) Ions with High Antimicrobial and Antibiofilm Activity, ACS Appl. Mater. Interfaces, 14, 390, 10.1021/acsami.1c21657 · DOI
- Wang, 2019, Anti-Biofilm Activity of Graphene Quantum Dots via Self-Assembly with Bacterial Amyloid Proteins, ACS Nano, 13, 4278, 10.1021/acsnano.8b09403 · DOI
- Ma, 2021, Structural mechanism for modulation of functional amyloid and biofilm formation by Staphylococcal Bap protein switch, EMBO J., 40, e107500, 10.15252/embj.2020107500 · DOI
- Nicastro, 2019, Bacterial Amyloids: The Link between Bacterial Infections and Autoimmunity, Trends Microbiol., 27, 954, 10.1016/j.tim.2019.07.002 · DOI
- Dizaj, 2014, Antimicrobial activity of the metals and metal oxide nanoparticles, Mater. Sci. Eng. C Mater. Biol. Appl., 44, 278, 10.1016/j.msec.2014.08.031 · DOI · Paper page
- Cui, 2012, The molecular mechanism of action of bactericidal gold nanoparticles on Escherichia coli, Biomaterials, 33, 2327, 10.1016/j.biomaterials.2011.11.057 · DOI · Paper page
- Zhang, 2020, A glycoconjugate-based gold nanoparticle approach for the targeted treatment of Pseudomonas aeruginosa biofilms, Nanoscale, 12, 23234, 10.1039/D0NR05365A · doi:10.1039/d0nr05365a
- Wang, 2019, Construction of nanomaterials with targeting phototherapy properties to inhibit resistant bacteria and biofilm infections, Chem. Eng. J., 358, 74, 10.1016/j.cej.2018.10.002 · DOI · Paper page
- Cui, 2020, Self-Propelled Active Photothermal Nanoswimmer for Deep-Layered Elimination of Biofilm In Vivo, Nano Lett., 20, 7350, 10.1021/acs.nanolett.0c02767 · DOI · Paper page
- 2015, Antibacterial and Antibiofilm Activities of the Photothermal Therapy Using Gold Nanorods against Seven Different Bacterial Strains, J. Nanomater., 2015, 783671, 10.1155/2015/783671 · DOI
- Khantamat, 2015, Gold Nanoshell-Decorated Silicone Surfaces for the Near-Infrared (NIR) Photothermal Destruction of the Pathogenic Bacterium E. faecalis, Acs Appl. Mater. Interfaces, 7, 3981, 10.1021/am506516r · DOI
- Jo, 2013, Influence of the photothermal effect of a gold nanorod cluster on biofilm disinfection, Nanotechnology, 24, 195104, 10.1088/0957-4484/24/19/195104 · DOI
- Dong, 2022, Intelligent peptide-nanorods against drug-resistant bacterial infection and promote wound healing by mild-temperature photothermal therapy, Chem. Eng. J., 432, 134061, 10.1016/j.cej.2021.134061 · DOI
- Fang, 2022, Near-infrared-activated nanohybrid coating with black phosphorus/zinc oxide for efficient biofilm eradication against implant-associated infections, Chem. Eng. J., 435, 134935, 10.1016/j.cej.2022.134935 · DOI
- Zhuang, 2021, Bifunctional cupric oxide nanoparticle-catalyzed self-cascade oxidation reactions of ascorbic acid for bacterial killing and wound disinfection, Compos. Part B Eng., 222, 109074, 10.1016/j.compositesb.2021.109074 · doi:10.1016/j.compositesb.2021.109074
- Mao, 2022, Iron oxide nanoparticles for biomedical applications: An updated patent review (2015–2021), Expert. Opin. Ther. Pat., 32, 939, 10.1080/13543776.2022.2109413 · DOI
- Armijo, L.M., Wawrzyniec, S.J., Kopciuch, M., Brandt, Y.I., Rivera, A.C., Withers, N.J., Cook, N.C., Huber, D.L., Monson, T.C., and Smyth, H.D.C. (2020). Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms. J. Nanobiotechnol., 18. · DOI · Paper page
- Somanathan, 2019, Silver nanoparticles: Electron transfer, reactive oxygen species, oxidative stress, beneficial and toxicological effects. Mini review, J. Appl. Toxicol., 39, 16, 10.1002/jat.3654 · DOI · Paper page
- Mann, R., Holmes, A., McNeilly, O., Cavaliere, R., Sotiriou, G.A., Rice, S.A., and Gunawan, C. (2021). Evolution of biofilm-forming pathogenic bacteria in the presence of nanoparticles and antibiotic: Adaptation phenomena and cross-resistance. J. Nanobiotechnol., 19. · DOI · Paper page
- Musielak, E., Feliczak-Guzik, A., and Nowak, I. (2022). Synthesis and Potential Applications of Lipid Nanoparticles in Medicine. Materials, 15. · DOI · Paper page
- Baek, 2018, A programmable lipid-polymer hybrid nanoparticle system for localized, sustained antibiotic delivery to Gram-positive and Gram-negative bacterial biofilms, Nanoscale Horiz., 3, 305, 10.1039/C7NH00167C · DOI
- Wan, 2018, Lipid Shell-Enveloped Polymeric Nanoparticles with High Integrity of Lipid Shells Improve Mucus Penetration and Interaction with Cystic Fibrosis-Related Bacterial Biofilms, ACS Appl. Mater. Interfaces, 10, 10678, 10.1021/acsami.7b19762 · DOI
- Ma, 2017, Application, mode of action, and in vivo activity of chitosan and its micro and nanoparticles as antimicrobial agents: A review, Carbohyd. Polym., 176, 257, 10.1016/j.carbpol.2017.08.082 · DOI · Paper page
- Jha, R., and Mayanovic, R.A. (2023). A Review of the Preparation, Characterization, and Applications of Chitosan Nanoparticles in Nanomedicine. Nanomaterials, 13. · DOI · Paper page
- Ma, 2020, Preparation and antibiofilm studies of curcumin loaded chitosan nanoparticles against polymicrobial biofilms of Candida albicans and Staphylococcus aureus, Carbohydr. Polym., 241, 116254, 10.1016/j.carbpol.2020.116254 · DOI
- Marangon, 2020, Combination of Rhamnolipid and Chitosan in Nanoparticles Boosts Their Antimicrobial Efficacy, Acs Appl. Mater. Interfaces, 12, 5488, 10.1021/acsami.9b19253 · DOI · Paper page
- Varshosaz, 2012, Dextran conjugates in drug delivery, Expert Opin. Drug Deliv., 9, 509, 10.1517/17425247.2012.673580 · DOI · Paper page
- Naha, 2019, Dextran-Coated Iron Oxide Nanoparticles as Biomimetic Catalysts for Localized and pH-Activated Biofilm Disruption, ACS Nano, 13, 4960, 10.1021/acsnano.8b08702 · DOI · Paper page
- Hu, 2021, Recent advances in dextran-based drug delivery systems: From fabrication strategies to applications, Carbohydr. Polym., 264, 117999, 10.1016/j.carbpol.2021.117999 · DOI · Paper page
- Barros, C.H.N., Hiebner, D.W., Fulaz, S., Vitale, S., Quinn, L., and Casey, E. (2021). Synthesis and self-assembly of curcumin-modified amphiphilic polymeric micelles with antibacterial activity. J. Nanobiotechnol., 19. · DOI
- Li, 2022, Destructing biofilms by cationic dextran through phase transition, Carbohydr. Polym., 279, 118778, 10.1016/j.carbpol.2021.118778 · DOI
- Hasannia, 2022, Synthesis of block copolymers used in polymersome fabrication: Application in drug delivery, J. Control Release, 341, 95, 10.1016/j.jconrel.2021.11.010 · DOI
- Konai, 2018, Recent Progress in Polymer Research to Tackle Infections and Antimicrobial Resistance, Biomacromolecules, 19, 1888, 10.1021/acs.biomac.8b00458 · DOI · Paper page
- Takahashi, 2016, Cationic Amphiphilic Polymers with Antimicrobial Activity for Oral Care Applications: Eradication of S. mutans Biofilm, Biomacromolecules, 18, 257, 10.1021/acs.biomac.6b01598 · DOI
- Zhao, 2020, Screening and Matching Amphiphilic Cationic Polymers for Efficient Antibiosis, Biomacromolecules, 21, 5269, 10.1021/acs.biomac.0c01330 · DOI
- Vishwakarma, 2021, Peptidomimetic Polyurethanes Inhibit Bacterial Biofilm Formation and Disrupt Surface Established Biofilms, J. Am. Chem. Soc., 143, 9440, 10.1021/jacs.1c02324 · DOI · Paper page
- Fadaka, A.O., Sibuyi, N.R.S., Madiehe, A.M., and Meyer, M. (2021). Nanotechnology-Based Delivery Systems for Antimicrobial Peptides. Pharmaceutics, 13. · DOI
- Hiemstra, 2016, Antimicrobial Peptides and Innate Lung Defenses: Role in Infectious and Noninfectious Lung Diseases and Therapeutic Applications, Chest, 149, 545, 10.1378/chest.15-1353 · DOI
- Travkova, 2017, The interaction of antimicrobial peptides with membranes, Adv. Colloid. Interface Sci., 247, 521, 10.1016/j.cis.2017.06.001 · DOI · Paper page
- Wang, 2022, Advances in the development of antimicrobial peptides and proteins for inhaled therapy, Adv. Drug Deliv. Rev., 180, 114066, 10.1016/j.addr.2021.114066 · DOI
- Nordstrom, 2017, Delivery systems for antimicrobial peptides, Adv. Colloid. Interface Sci., 242, 17, 10.1016/j.cis.2017.01.005 · DOI · Paper page
- Wang, 2021, Antimicrobial peptides towards clinical application: Delivery and formulation, Adv. Drug Deliv. Rev., 175, 113818, 10.1016/j.addr.2021.05.028 · DOI · Paper page
- Casciaro, 2019, Poly(lactide- co-glycolide) Nanoparticles for Prolonged Therapeutic Efficacy of Esculentin-1a-Derived Antimicrobial Peptides against Pseudomonas aeruginosa Lung Infection: In Vitro and in Vivo Studies, Biomacromolecules, 20, 1876, 10.1021/acs.biomac.8b01829 · DOI
- Falciani, 2020, Antimicrobial Peptide-Loaded Nanoparticles as Inhalation Therapy for Pseudomonas aeruginosa Infections, Int. J. Nanomed., 15, 1117, 10.2147/IJN.S218966 · doi:10.2147/ijn.s218966
- Yu, 2020, Demolishing the great wall of biofilms in Gram-negative bacteria: To disrupt or disperse?, Med. Res. Rev., 40, 1103, 10.1002/med.21647 · DOI
- Rivero Berti, I., Islan, G.A., and Castro, G.R. (2021). Enzymes and biopolymers. The opportunity for the smart design of molecular delivery systems. Bioresour. Technol., 322. · DOI
- Conte, 2014, Improving the efficacy of inhaled drugs in cystic fibrosis: Challenges and emerging drug delivery strategies, Adv. Drug Deliv. Rev., 75, 92, 10.1016/j.addr.2014.05.008 · DOI
- Tan, 2018, Enhancing antibiofilm activity with functional chitosan nanoparticles targeting biofilm cells and biofilm matrix, Carbohydr. Polym., 200, 35, 10.1016/j.carbpol.2018.07.072 · DOI
- Tasia, 2020, Enhanced eradication of bacterial biofilms with DNase I-loaded silver-doped mesoporous silica nanoparticles, Nanoscale, 12, 2328, 10.1039/C9NR08467C · DOI
- Zhu, 2015, Alginate lyase: Review of major sources and classification, properties, structure-function analysis and applications, Bioengineered, 6, 125, 10.1080/21655979.2015.1030543 · DOI · Paper page
- Daboor, 2021, Disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate lyase enhances pathogen eradication by antibiotics, J. Cyst. Fibros., 20, 264, 10.1016/j.jcf.2020.04.006 · doi:10.1016/j.jcf.2020.04.006
- Baker, 2016, Exopolysaccharide biosynthetic glycoside hydrolases can be utilized to disrupt and prevent Pseudomonas aeruginosa biofilms, Sci. Adv., 2, e1501632, 10.1126/sciadv.1501632 · DOI · Paper page
- Thorn, 2021, Protective Liquid Crystal Nanoparticles for Targeted Delivery of PslG: A Biofilm Dispersing Enzyme, ACS Infect. Dis., 7, 2102, 10.1021/acsinfecdis.1c00014 · DOI
- Mukherjee, 2019, Bacterial quorum sensing in complex and dynamically changing environments, Nat. Rev. Microbiol., 17, 371, 10.1038/s41579-019-0186-5 · DOI · Paper page
- Carradori, 2020, Biofilm and Quorum Sensing inhibitors: The road so far, Expert Opin. Ther. Pat., 30, 917, 10.1080/13543776.2020.1830059 · DOI
- Duplantier, M., Lohou, E., and Sonnet, P. (2021). Quorum Sensing Inhibitors to Quench P. aeruginosa Pathogenicity. Pharmaceuticals, 14. · DOI
- Zhao, X., Yu, Z., and Ding, T. (2020). Quorum-Sensing Regulation of Antimicrobial Resistance in Bacteria. Microorganisms, 8. · DOI · Paper page
- Defoirdt, 2018, Quorum-Sensing Systems as Targets for Antivirulence Therapy, Trends Microbiol., 26, 313, 10.1016/j.tim.2017.10.005 · DOI · Paper page
- Welsh, 2015, Small molecule disruption of quorum sensing cross-regulation in Pseudomonas aeruginosa causes major and unexpected alterations to virulence phenotypes, J. Am. Chem. Soc., 137, 1510, 10.1021/ja5110798 · DOI · Paper page
- Welsh, 2016, Chemical probes of quorum sensing: From compound development to biological discovery, FEMS Microbiol. Rev., 40, 774, 10.1093/femsre/fuw009 · DOI · Paper page
- Schutz, 2018, Targeting the Pseudomonas quinolone signal quorum sensing system for the discovery of novel anti-infective pathoblockers, Beilstein J. Org. Chem., 14, 2627, 10.3762/bjoc.14.241 · DOI
- Ho, 2020, Squalenyl Hydrogen Sulfate Nanoparticles for Simultaneous Delivery of Tobramycin and an Alkylquinolone Quorum Sensing Inhibitor Enable the Eradication of P. aeruginosa Biofilm Infections, Angew. Chem. Int. Ed. Engl., 59, 10292, 10.1002/anie.202001407 · doi:10.1002/anie.202001407
- Jenal, 2017, Cyclic di-GMP: Second messenger extraordinaire, Nat. Rev. Microbiol., 15, 271, 10.1038/nrmicro.2016.190 · DOI · Paper page
- Hengge, 2009, Principles of c-di-GMP signalling in bacteria, Nat. Rev. Microbiol., 7, 263, 10.1038/nrmicro2109 · DOI · Paper page
- Cai, 2021, NO donors and NO delivery methods for controlling biofilms in chronic lung infections, Appl. Microbiol. Biotechnol., 105, 3931, 10.1007/s00253-021-11274-2 · DOI · Paper page
- Bartley, 2020, High-Dose Inhaled Nitric Oxide as Adjunct Therapy in Cystic Fibrosis Targeting Burkholderia multivorans, Case Rep. Pediat, 2020, 1536714
- Miller, 2012, A phase I clinical study of inhaled nitric oxide in healthy adults, J. Cyst. Fibros., 11, 324, 10.1016/j.jcf.2012.01.003 · DOI
200 of 252 shown
Cited by
Antimicrobial nanoparticles: current landscape and future challenges
Mondal, S. K., Chakraborty, S., Manna, S., & Mandal, S. M. (2024) · RSC Pharmaceutics · doi:10.1039/d4pm00032c · Cited by 318
Elbehiry, A., Marzouk, E., Edrees, H. M., Ibrahem, M., Alzahrani, S., Anagreyyah, S., Abualola, H., Alghamdi, A., Alzahrani, A., Jaber, M., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14010109 · Cited by 34
Metadata
- Authors
- Guo, Y., Mao, Z., Ran, F., Sun, J., Zhang, J., Chai, G., & Wang, J.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2023-11-03
- Volume
- 15
- Issue
- 11
- Pages
- 2582
- ISSN
- 1999-4923
- Cited by
- 67
- References
- 4
- Language
- en
- Funders
- Open Project of State Key Laboratory of Respiratory Disease (SKLRD-OP-202302, 2023A1515011064, A2023090, 22qntd4503, 2019E10020 (KFJJ-202202))
- Guangdong Basic and Applied Basic Research Foundation (SKLRD-OP-202302, 2023A1515011064, A2023090, 22qntd4503, 2019E10020 (KFJJ-202202))
- Medical Scientific Research Foundation of Guangdong Province (SKLRD-OP-202302, 2023A1515011064, A2023090, 22qntd4503, 2019E10020 (KFJJ-202202))
- Fundamental Research Funds for the Central Universities (SKLRD-OP-202302, 2023A1515011064, A2023090, 22qntd4503, 2019E10020 (KFJJ-202202))
- Open Project of The Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province (SKLRD-OP-202302, 2023A1515011064, A2023090, 22qntd4503, 2019E10020 (KFJJ-202202))
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections. https://app.cochat.ai/papers/10.3390/pharmaceutics15112582
- The paper
- Guo, Y., Mao, Z., Ran, F., Sun, J., Zhang, J., Chai, G., & Wang, J. (2023). Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections. Pharmaceutics. https://doi.org/10.3390/pharmaceutics15112582
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.